Regulation 24A for the period ended march 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shukra Pharmaceuticals has filed its Annual Secretarial Compliance Report for the year ended March 31, 2026, prepared by Practicing Company Secretary Rupal Patel. The report confirms the company has complied with all applicable SEBI regulations, Secretarial Standards, and maintained proper Board processes. Four new subsidiaries were incorporated during the year: Shukra Diabetes Technologies, Shukra Healthtech, Shukra Robotics, and Shukra WoundCare (all Private Limited). The company issued 46,43,000 Convertible Equity Warrants to promoters at Rs.34 per warrant (including Rs.33 premium), with BSE in-principal approval received on January 9, 2026 and allotment completed on January 28, 2026. Director changes occurred with Mr. Dinesh Chauhan appointed as Additional Independent Director and Ms. Bhoomi Patel resigning, both effective December 30, 2025. The statutory auditor was changed from M/s. Maak & Associates to M/s. Shah Sanghvi & Associates in August 2025. Past minor delays from the previous year (two 1-day delays in filings) resulted in total fines of Rs.14,160, all of which were paid.
Generally positive for shareholders. The company has demonstrated compliance with SEBI regulations and proper corporate governance. The equity warrant issuance to promoters and new subsidiary formations indicate business expansion plans. Minor past compliance delays were already penalized and resolved.